Hydroxyurea has hematological and clinical efficacy in SCA, but its effects on transcranial doppler (TCD) flow velocities remain undefined. Fifty-nine children initiating hydroxyurea therapy for clinical severity had pre-treatment baseline TCD measurements; 37 with increased flow velocities (≥140 cm/sec) were then enrolled in an IRB-approved prospective Phase II trial with TCD velocities measured at maximum tolerated dose (MTD) and one year later. At hydroxyurea MTD (mean ± 1SD = 27.9 ± 2.7 mg/kg/day), significant decreases were observed in the right MCA (166 ± 27 cm/sec to 135 ± 27 cm/sec, p<.001) and left MCA velocities (168 ± 26 cm/sec to 142 ± 27 cm/sec, p<.001).
INTRODUCTION
Transcranial doppler (TCD) ultrasonography is now recommended as a routine screening test for children with sickle cell anemia (SCA) from 2 to 16 years of age, to identify patients at highest risk for primary stroke [1, 2] . TCD studies measure flow velocity within the large intracranial arteries, which are the vessels most often involved in sickle cerebral vasculopathy and stroke [3, 4] . TCD ultrasonography is particularly useful in children because it is painless, non-invasive, relatively inexpensive, easy to perform, and requires no sedation.
Landmark studies performed almost two decades ago by Adams and colleagues [5] found that children with SCA have higher baseline TCD flow velocities than agematched children without SCA. These increased TCD velocities were related in part to the anemia, since the TCD values were inversely correlated with the hematocrit [6] .
Among children with SCA, however, increased TCD flow velocities have also been associated with younger age and pathological arterial stenosis [7] . In the cohort of patients from the Medical College of Georgia, 36.8% had TCD velocities ≥ 140 cm/sec, 17.5% had velocities ≥ 170 cm/sec termed "conditional", and 7.9% had velocities ≥ 200 cm/sec termed "abnormal" [5, 8, 9] .
Abnormal TCD velocities are identified in 5-10% of children with SCA and confer a 10% annual risk for developing primary stroke [8, 9] . The NHLBI-sponsored multicenter randomized Stroke Prevention (STOP) trial demonstrated that monthly blood transfusions can reduce this stroke risk by 90% compared to observation alone [10] , and a Clinical Alert recommended chronic transfusions for children with SCA and abnormal TCD velocities [11] . However, the follow-up STOP 2 study concluded that transfusions must For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From be continued indefinitely in this setting, due to an increased risk of conversion to abnormal TCD velocities and the development of new neurological events after halting transfusions [12] . Children with conditional TCD velocities also have an elevated (1-3% annual) risk of developing primary stroke, most commonly after conversion to the abnormal category [13] . Accordingly, frequent monitoring of children with conditional TCD velocities is recommended, although no specific therapy is currently recommended for this potentially vulnerable patient population.
An alternative effective therapy would be beneficial for children with SCA and abnormal TCD velocities to reduce the long-term risks associated with chronic blood transfusions, including erythrocyte alloimmunization, infectious risks, and iron overload [14] . In addition, a simple treatment option might be beneficial for children with conditional TCD values, who currently receive increased monitoring but no specific treatment. The increasing availability of hydroxyurea therapy offers a reasonable therapeutic option in these settings, but to date no prospective studies have focused on the effects of hydroxyurea therapy on TCD velocities in children with SCA. The Belgian registry recently reported a beneficial effect of hydroxyurea in 11 children who had abnormal TCD and serial measurements, with a significant decrease observed in TCD velocities [15] . A recent small retrospective analysis suggested that hydroxyurea significantly decreased the TCD velocities compared to age-matched controls, but only 8 children had TCD velocities ≥ 140 cm/sec and the effects were not related to hematological changes [16] . In the current study, we describe a prospective singleinstitution IRB-approved Phase II trial of hydroxyurea for children with SCA and increased TCD flow velocities. All TCD screening studies were performed in the Neurodiagnostic Laboratory at Duke University Medical Center using a non-duplex TCD instrument, according to the published techniques for children with SCA [5] . Briefly, the left and right middle cerebral, distal internal carotid, anterior cerebral, and posterior cerebral arteries were insonated at 2mm increments using a special pediatric transducer and a transtemporal approach.
Maximal systolic and diastolic peak velocities were recorded, but the time-averaged For personal use only. on September 14, 2017. by guest www.bloodjournal.org From maximum velocity (TAMV) was used to determine the TCD value for the major intracranial arteries on each side, as previously described [5] .
After TCD screening, those children with at least one increased TCD value (defined as a right-or left-sided TAMV ≥ 140 cm/sec) were offered enrollment in an IRBapproved trial to determine prospectively the effects of hydroxyurea therapy on TCD velocities. Approval for this prospective study was obtained from the Duke University Medical Center Institutional Review Board and all subjects and families gave written informed consent. Hydroxyurea dosing and monitoring were performed according to routine clinical practice, including escalation to the maximum tolerated dose (MTD) with monthly blood counts as previously described [17] . After a stable hydroxyurea MTD was reached, typically after 6-12 months of therapy, a follow-up TCD study was performed. A third long-term follow-up TCD study was then performed at least one year after reaching MTD, to determine if there were sustained treatment effects. Baseline brain MRI/MRA imaging was performed in children as part of this protocol, using standard techniques.
Statistical analysis. TCD flow velocities were recorded for the right and left middle cerebral artery (MCA), anterior cerebral artery (ACA), and posterior cerebral artery (PCA).
Patient and treatment characteristics such as age, hydroxyurea dose, and routine blood counts including % HbF values, were also recorded. Standard statistical calculations such as mean ± standard deviation, median, and range were performed using Excel software. Comparisons of TCD studies for a given patient, e.g. pre-and post-treatment with hydroxyurea, were performed using the nonparametric Wilcoxon rank sum test while between-group comparisons used a two-tailed t test. Regression plots to determine For personal use only. on September 14, 2017. by guest www.bloodjournal.org From correlations between parameters such as baseline TCD velocity and change in TCD values were performed using SAS software (Cary, NC).
RESULTS
Initial TCD Screening. Analysis of the first 102 children who received TCD screening [18] revealed fewer than expected children with conditional and abnormal flow velocities (12.7% and 3.9% respectively), compared to Adams's published prevalence values of 17.5% and 7.9% [8, 9] . Subsequent analysis of these initial screening results according to concurrent hydroxyurea therapy revealed a significant difference: 28 children on hydroxyurea therapy had an average TCD flow velocity of 116 ± 25 cm/sec, while 74 children not on hydroxyurea therapy had an average TCD flow velocity of 141 ± 32 cm/sec (p<.001, data not shown). These pilot data suggested that hydroxyurea therapy might lead to decreased TCD flow velocities, but no baseline pre-treatment measurements were available, and there were substantial differences between these two patient cohorts (e.g., the hydroxyurea-treated children were older and had more clinical severity). To test this hypothesis, we designed a prospective Phase II study to determine the effects of hydroxyurea therapy on TCD flow velocities in children with SCA.
TCD screening for Phase II study eligibility. Over a 45-month period, 59 children with SCA underwent TCD screening before initiating hydroxyurea therapy for clinical indications (e.g., pain, ACS). A total of 37 children (62.7%) were identified with at least one increased TCD velocity value Table 1 . Their pre-treatment laboratory values were very similar to those reported in the HUG-KIDS trial [19] . The average pre-treatment TCD velocities were highest in the MCA, followed by ACA and then PCA vessels, but no significant differences were observed between the right-and left-sided vessels.
All 37 children were treated with hydroxyurea and eventually reached a stable MTD of 27.9 ± 2.7 mg/kg/day (median 28.6, range 18.8 to 32.6 mg/kg/day). Compliance
with hydroxyurea therapy was estimated to be excellent for most of the patients, although six children (16%) had presumed poor medication adherence based on hematological parameters and failure to attend clinic appointments regularly. Laboratory values at hydroxyurea MTD for the entire cohort of 37 patients illustrate the expected significant increases in hemoglobin concentration, hematocrit, MCV, and %HbF (Table 1) First, the positive predictive value of an abnormal TCD result for stroke is relatively low, since only one-third of children with abnormal TCD velocities and even fewer with conditional TCD velocities will develop an overt clinical stroke [8, 9] . Long-term follow-up from the original STOP trial has also identified a subset of patients who remain strokefree off transfusions despite persistent abnormal TCD flow velocities, and also some transfused patients who continue to have abnormal TCD velocities [20] . Discordance between TCD and brain MRI/MRA results is also recognized, including the observation that most children with abnormal TCD velocities will have no abnormalities on brain MRI or MRA [21, 22] . In addition, there are well recognized risks of blood transfusions, including iron overload and alloimmunization, for children with SCA receiving indefinite monthly transfusions in accordance with current NHLBI recommendations for abnormal TCD velocities. In the STOP trial, 10 of 63 subjects randomized to the transfusion arm developed new RBC alloantibodies, despite extended phenotypic matching of blood, 5 required central line placement to facilitate transfusions, and almost all of the patients had increases in serum ferritin to the range requiring initiation of iron chelation therapy [23, 24] .
Finally, the projected costs of chronic blood transfusions (including chelation therapy) approaches $400,000 per patient decade [25] . Taken together, these observations suggest that an alternative and effective treatment for primary stroke prevention would be a useful option for patients with SCA and an abnormal TCD velocity.
Although monthly transfusions are currently recommended for children with abnormal TCD velocities, the mechanisms by which transfusions reduce stroke risk have not been fully elucidated. Acutely, transfused erythrocytes quickly raise the circulating erythrocyte mass and increase the hematocrit with concomitant increased blood viscosity, and have been demonstrated to lower the TCD velocity within 30 minutes of starting the transfusion [26] . Chronic transfusion therapy also directly inhibits erythrocyte sickling, improves blood rheology, reduces red cell adhesion, and lowers the plasma-free hemoglobin and other laboratory evidence of hemolysis [27] [28] [29] . Similar effects are observed in association with hydroxyurea therapy, which also increases the hematocrit, inhibits erythrocyte sickling by increased fetal hemoglobin, improves red cell rheology, reduces red cell adhesion, and lowers LDH and total bilirubin concentrations [19, [30] [31] [32] .
Both transfusions and hydroxyurea therapy might, therefore, be expected to lower TCD flow velocities in children with SCA. In the setting of secondary stroke prevention, hydroxyurea therapy has been shown to provide similar protection as transfusion prophylaxis [33, 34] .
Gulbis and colleagues [15] recently reported updated results from the Belgian registry, which included 34 children with SCA at risk for primary stroke on the basis of an abnormal TCD. Although these patients were treated with hydroxyurea below MTD (median dose <20 mg/kg/day), 11 children with serial TCD measurements had a significant decrease in TCD velocities from 235 ± 25 cm/sec to 204 ± 27 cm/sec (p<.01). SZ designed and performed the study, and wrote the paper; WS, SB, and NB enrolled the patients and performed the study; RW designed the study and wrote the paper. The authors also acknowledge the efforts and support of Dr. Daniel Laskowitz for assistance with TCD examinations, Jacqueline Davis and Tracey Kelly for clinical care, and Matthew Smeltzer for statistical assistance. 
